{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:03:59Z","timestamp":1773288239650,"version":"3.50.1"},"reference-count":22,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2004,6,21]],"date-time":"2004-06-21T00:00:00Z","timestamp":1087776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2004,10]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold><jats:bold> Introduction:\u2002<\/jats:bold> A combination of fractionated total body irradiation (TBI) with etoposide (VP\u201016) and cyclophosphamide (CY) as a preconditioning regimen (VP\/CY\/TBI) has been reported to be safe and effective for both adults and children undergoing allogeneic bone marrow transplantation (allo\u2010BMT). However, the reported doses of VP\u201016 were different. We evaluated the efficacy and safety of a VP\u201016 (at less than the usual dose)\/CY\/TBI regimen for adults with hematological malignancies who are required to receive allo\u2010BMT.<\/jats:p><jats:p><jats:bold>Patients and methods:\u2002<\/jats:bold> Thirty\u2010eight patients received VP\u201016, CY and TBI (VP\/CY\/TBI) as a preconditioning regimen for allo\u2010BMT. Twenty\u2010one patients were in first complete remission (1CR), six patients were in second remission (2CR) and 11 patients were in non\u2010remission status (non\u2010CR) before allo\u2010BMT. These patients received allo\u2010BMT from related donors (n\u2003=\u200314) and unrelated donors (n\u2003=\u200324). The preconditioning regimen consisted of VP\u201016 (15\u2003mg\/kg\/d for 2\u2003d), CY (60\u2003mg\/kg\/d for 2\u2003d) and 12\u2003Gy TBI in six fractions for 3\u2003d.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Two patients died on day 30 after transplantation. The median follow\u2010up period for all patients was 35.0\u2003months (range 0.8\u2013159.6\u2003months). At the time of analysis, 10 patients had died. Seven of those 10 patients died because of relapse. The estimated 5\u2010yr disease\u2010free survival (DFS) rates for all cases and acute myelogenous leukemia and acute lymphoblastic leukemia cases were 73.6, 66.7 and 100%, respectively. The estimated 5\u2010yr DFS rates for 1CR, 2CR and non\u2010CR cases were 90.5, 83.3 and 40.9%, respectively (p\u2003&lt;\u20030.05).<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> Based on these findings, we suggest that a VP\/CY\/TBI regimen is effective and safe for adult patients with hematological malignancies in 1CR and 2CR.<\/jats:p>","DOI":"10.1111\/j.1399-0012.2004.00225.x","type":"journal-article","created":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T15:20:15Z","timestamp":1094052015000},"page":"552-557","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy of etoposide, cyclophosphamide, and total body irradiation in allogeneic bone marrow transplantation for adult patients with hematological malignancies"],"prefix":"10.1111","volume":"18","author":[{"given":"Tomomi","family":"Toubai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Hashino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Kahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko","family":"Izumiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakatu","family":"Yonezumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyasu","family":"Toyoshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Asaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,9]]},"reference":[{"key":"e_1_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198712243172602"},{"key":"e_1_2_12_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-8-590"},{"key":"e_1_2_12_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198312013092202"},{"key":"e_1_2_12_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V71.4.888.888"},{"key":"e_1_2_12_6_2","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1182\/blood.V72.5.1567.1567","article-title":"Fractionated total body irradiation and high\u2010dose VP\u201016\u2013213 followed by allogeneic bone marrow transplantation in advanced leukemias","volume":"72","author":"Schmitz N","year":"1988","journal-title":"Blood"},{"key":"e_1_2_12_7_2","first-page":"559","article-title":"Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation","volume":"4","author":"Spitzer TR","year":"1989","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_12_8_2","first-page":"83","article-title":"Bone marrow transplantation for advanced acute leukemia: a pilot study of high\u2010energy total body irradiation, cyclophosphamide and continuous infusion etoposide","volume":"5","author":"Bostrom B","year":"1990","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_12_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830410108"},{"key":"e_1_2_12_10_2","first-page":"83","article-title":"Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase 1 study","volume":"10","author":"Petersen FB","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_12_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)90224-0"},{"key":"e_1_2_12_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.9.1923"},{"key":"e_1_2_12_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.5.1391.bloodjournal8551391"},{"key":"e_1_2_12_14_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609051758"},{"key":"e_1_2_12_15_2","first-page":"324","article-title":"Fractionated total\u2010body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high\u2010risk or advanced\u2010stage hematological malignancies","volume":"3","author":"Long GD","year":"1997","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_12_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702181"},{"key":"e_1_2_12_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-197410000-00001"},{"key":"e_1_2_12_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90380-0"},{"key":"e_1_2_12_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.1767"},{"key":"e_1_2_12_20_2","first-page":"2434","article-title":"Synergistic effect of 4\u2010hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL\u201060) demonstrated by computer analysis","volume":"45","author":"Chang TT","year":"1985","journal-title":"Cancer Res"},{"key":"e_1_2_12_21_2","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1182\/blood.V81.8.2187.2187","article-title":"A prospective randomized comparison of total body irradiation\u2010etoposide versus busulfan\u2013cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study","volume":"81","author":"Blume KG","year":"1993","journal-title":"Blood"},{"key":"e_1_2_12_22_2","first-page":"763","article-title":"Relapsed acute lymphoblastic leukemia: similar outcomes for autologous and allogeneic marrow transplantation in selected children","volume":"17","author":"Parsons SK","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_12_23_2","first-page":"85","article-title":"Hyperacute graft\u2010versus\u2010host disease accompanied by increased serum interleukin\u20106 levels","volume":"60","author":"Imamura M","year":"1994","journal-title":"Int J Hematol"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-0012.2004.00225.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-0012.2004.00225.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T17:42:45Z","timestamp":1697218965000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-0012.2004.00225.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["10.1111\/j.1399-0012.2004.00225.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-0012.2004.00225.x","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}